C Michael Gibson/Baim Institute
Feb 16, 2026, 06:21
C. Michael Gibson: Favorable Safety Outcomes With Asundexian
C. Michael Gibson, President and CEO at Baim Institute for Clinical Research, Professor of Medicine at Harvard Medical School, and Executive Board Member at EXCITE International, shared a post on LinkedIn:
”No increase in any type of bleeding with Asundexian. Even minor bleeding was not increased (was numerically lower).”
Stay updated with Hemostasis Today.
-
Apr 2, 2026, 18:16Saravanan Subramaniam: How Extracellular Histones Act as Key Drivers of Thromboinflammation
-
Apr 2, 2026, 18:06Rob Molhoek Brings Invaluable Insights on Stroke Awareness and Care Improvements – Stroke Foundation
-
Apr 2, 2026, 17:21Paul Bolaji: Phase 2 of the Nigeria National Stroke Registry Is Now Live
-
Apr 2, 2026, 17:13Catherine Jennings: Marking Today as an Important Step Forward for Patients With PE
-
Apr 2, 2026, 17:11Arun V. J: Our Clinical Audit on Transfusion Safety Selected for Presentation at CAHOCON 2026
-
Apr 2, 2026, 17:10Maxime Dely: Better Collection, Better Blood – The Quality Starts Now
-
Apr 2, 2026, 17:09Arun Danewa: Saving a Bone Marrow Patient from Hidden Enemy – TA-TMA
-
Apr 2, 2026, 17:07Cathy Harrison: The WFH Nurses Committee are Looking for New Members
-
Apr 2, 2026, 16:30Sam K. Saha: The Hardest Cases Are the Ones You Can’t Save